Noble metals such as gold and silver have been appreciated for millennia not only for their beauty but also for their ability to fight diseases. Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique physiochemical and chemical properties as well as biological features, such as anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial activities I
Noble metals such as gold and silver have been appreciated for millennia not only for their
beauty but also for their ability to fight diseases.
Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique
physiochemical and chemical properties as well as biological features, such as
anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial
activities Infectious diseases account for more than 20% of global mortality and viruses are
responsible for about one-third of these deaths. Highly infectious viral diseases such as
severe acute respiratory (SARS), Middle East respiratory syndrome (MERS) and coronavirus
disease (COVID-19) are emerging more frequently and their worldwide spread poses a serious
threat to human health and the global economy.
The current COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) .
Drug: Colloidal Silver
Orally: colloidal silver 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)
and By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days.
Other Name: Experimental
Drug: Placebo
Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days.
Inclusion Criteria:
- Inclusion of any patient, over the age of 18, consulting the Sahloul emergencies,
Sousse for symptoms of COVID -19 dating less than 10 days and having a positive
COVID-19 on the PCR test and typical scanner.
Exclusion Criteria:
- Any pregnant or breastfeeding woman
- patient with an expectation of survival of less than 24 hours
- Dyspnea leading to heart failure
- Hepatic insufficiency
- Chronic respiratory failure
- Renal failure, clearance <20ml • min-1 • 1.73 • m-²
HU Sahloul, sousse, Tunisia
Sousse, Itinéraire Ceinture Cité Sahloul, Tunisia
Investigator: boukef riadh, professor
Contact: 73 369 411
riadboukef@gmail.com
Boukef Riadh, professor
00 216 98 676 745
riadboukef@gmail.com
Boukef Riadh, professor, Principal Investigator
HU Sahloul